On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Johnson & Johnson is advancing Alzheimer’s research through precision medicine, focusing on tau-targeting therapies like ...
Last month, the U.S. Food and Drug Administration issued a complete response letter (CRL) to Johnson & Johnson's Biologics License Application for a fixed combination of amivantamab and recombinant ...
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine ...
Amid a deluge of executive actions, the Trump administration has directed federal health agencies to pause external ...
The U.S. Department of Health and Human Services has paused public communications until Feb. 1 as Trump appointees take ...